Skip to main content
. 2022 Apr 4;14(4):788. doi: 10.3390/pharmaceutics14040788

Figure 1.

Figure 1

Schematic overview of the strategy proposed. (A) Chemical structures of the CD44 inhibitors. (B) Specific release of the THIQ inhibitor JE22 bound to the nanodevice JE22-NPs (5) as a result of the acidic environment in the cancer cells, and subsequent therapeutic activity by its binding to CD44.